MeCP2	B-GP
-	O
Related	O
Diseases	O
and	O
Animal	B-OG
Models	O

The	O
role	O
of	O
epigenetics	O
in	O
human	B-OG
disease	O
has	O
become	O
an	O
area	O
of	O
increased	O
research	O
interest	O
.	O

Collaborative	O
efforts	O
from	O
scientists	O
and	O
clinicians	O
have	O
led	O
to	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
by	O
which	O
epigenetic	O
regulation	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
many	O
human	B-OG
diseases	O
.	O

Several	O
neurological	O
and	O
non	O
-	O
neurological	B-DS
disorders	I-DS
are	O
associated	O
with	O
mutations	O
in	O
genes	O
that	O
encode	O
for	O
epigenetic	O
factors	O
.	O

One	O
of	O
the	O
most	O
studied	O
proteins	O
that	O
impacts	O
human	B-OG
disease	O
and	O
is	O
associated	O
with	O
deregulation	O
of	O
epigenetic	O
processes	O
is	O
Methyl	B-GP
CpG	I-GP
binding	I-GP
protein	I-GP
2	I-GP
(	O
MeCP2	B-GP
).	O

MeCP2	B-GP
is	O
an	O
epigenetic	O
regulator	O
that	O
modulates	O
gene	O
expression	O
by	O
translating	O
epigenetic	O
DNA	O
methylation	O
marks	O
into	O
appropriate	O
cellular	O
responses	O
.	O

In	O
order	O
to	O
highlight	O
the	O
importance	O
of	O
epigenetics	O
to	O
development	O
and	O
disease	O
,	O
we	O
will	O
discuss	O
how	O
MeCP2	B-GP
emerges	O
as	O
a	O
key	O
epigenetic	O
player	O
in	O
human	B-OG
neurodevelopmental	O
,	O
neurological	O
,	O
and	O
non	O
-	O
neurological	B-DS
disorders	I-DS
.	O

We	O
will	O
review	O
our	O
current	O
knowledge	O
on	O
MeCP2	B-GP
-	O
related	O
diseases	O
,	O
including	O
Rett	B-DS
Syndrome	I-DS
,	O
Angelman	B-DS
Syndrome	I-DS
,	O
Fetal	B-DS
Alcohol	I-DS
Spectrum	I-DS
Disorder	I-DS
,	O
Hirschsprung	B-DS
disease	I-DS
,	O
and	O
Cancer	B-DS
.	O

Additionally	O
,	O
we	O
will	O
briefly	O
discuss	O
about	O
the	O
existing	O
MeCP2	B-GP
animal	B-OG
models	O
that	O
have	O
been	O
generated	O
for	O
a	O
better	O
understanding	O
of	O
how	O
MeCP2	B-GP
impacts	O
certain	O
human	B-OG
diseases	O
.	O

1	O
.	O

Introduction	O

Methyl	B-GP
CpG	I-GP
binding	I-GP
protein	I-GP
2	I-GP
(	O
MeCP2	B-GP
)	O
was	O
first	O
identified	O
and	O
characterized	O
as	O
a	O
DNA	B-GP
binding	I-GP
protein	I-GP
that	O
specifically	O
binds	O
to	O
methyl	O
-	O
CpG	O
dinucleotides	O
[	O
1	O
].	O

The	O
MECP2	B-GP
gene	O
is	O
localized	O
on	O
the	O
X	O
-	O
chromosome	O
and	O
contains	O
complex	O
regulatory	O
elements	O
that	O
control	O
its	O
precise	O
expression	O
levels	O
[	O
2	O
–	O
5	O
].	O

In	O
both	O
human	B-OG
and	O
mouse	B-OG
,	O
the	O
MECP2	B-GP
/	O
Mecp2	B-GP
gene	O
consists	O
of	O
four	O
exons	O
encoding	O
for	O
two	O
different	O
protein	O
isoforms	O
,	O
MeCP2E1	O
and	O
MeCP2E2	O
[	O
6	O
,	O
7	O
].	O

The	O
two	O
Mecp2	B-GP
/	O
MeCP2	B-GP
isoforms	O
show	O
differential	O
temporal	O
and	O
brain	O
region	O
-	O
specific	O
differences	O
in	O
their	O
distribution	O
[	O
7	O
],	O
and	O
we	O
previously	O
showed	O
that	O
MeCP2E1	O
isoform	O
is	O
similarly	O
distributed	O
compared	O
to	O
total	O
MeCP2	B-GP
in	O
murine	O
brain	O
cells	O
[	O
8	O
].	O

The	O
main	O
functional	O
protein	O
domains	O
of	O
MeCP2	B-GP
include	O
the	O
methyl	O
binding	O
domain	O
(	O
MBD	O
),	O
the	O
transcriptional	O
repression	O
domain	O
(	O
TRD	O
),	O
the	O
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
),	O
and	O
the	O
inter	O
domain	O
(	O
ID	O
)	O
[	O
9	O
,	O
10	O
].	O

The	O
MBD	O
facilitates	O
binding	O
to	O
methylated	O
CpG	O
dinucleotides	O
and	O
the	O
preference	O
for	O
adjacent	O
A	O
/	O
T	O
-	O
rich	O
motifs	O
[	O
9	O
,	O
11	O
].	O

It	O
is	O
also	O
capable	O
of	O
binding	O
to	O
non	O
-	O
methylated	O
DNA	O
sequences	O
such	O
as	O
the	O
four	O
-	O
way	O
DNA	O
junctions	O
[	O
12	O
,	O
13	O
].	O

The	O
TRD	O
domain	O
mediates	O
the	O
transcriptional	O
repressor	O
role	O
of	O
MeCP2	B-GP
,	O
and	O
interacts	O
with	O
co	O
-	O
repressor	O
complexes	O
,	O
such	O
as	O
c	B-GP
-	I-GP
Ski	I-GP
,	O
mSin3A	B-GP
,	O
HDAC1	B-GP
,	O
and	O
HDAC2	B-GP
[	O
5	O
,	O
9	O
,	O
14	O
,	O
15	O
].	O

The	O
CTD	O
is	O
suggested	O
to	O
be	O
important	O
for	O
MeCP2	B-GP
function	O
and	O
its	O
chromatin	O
binding	O
activities	O
[	O
12	O
].	O

Inter	O
domain	O
interactions	O
significantly	O
impacts	O
MeCP2	B-GP
structure	O
and	O
increases	O
the	O
stability	O
of	O
the	O
protein	O
[	O
16	O
,	O
17	O
].	O

MeCP2	B-GP
is	O
a	O
nuclear	O
protein	O
that	O
is	O
mainly	O
localized	O
to	O
methylated	O
pericentromeric	O
heterochromatin	O
,	O
referred	O
to	O
as	O
chromocenters	O
[	O
18	O
].	O

MeCP2	B-GP
is	O
widely	O
expressed	O
in	O
several	O
tissues	O
,	O
and	O
is	O
suggested	O
to	O
mediate	O
transcriptional	O
regulation	O
through	O
association	O
with	O
5	O
-	O
methyl	O
cytosine	O
(	O
5mC	O
)	O
and	O
5	O
-	O
hydroxymethlcytosine	O
(	O
5hmC	O
),	O
the	O
two	O
major	O
types	O
of	O
DNA	O
modifications	O
[	O
19	O
–	O
21	O
].	O

MeCP2	B-GP
binding	O
to	O
5mC	O
is	O
associated	O
with	O
repressive	O
functions	O
through	O
its	O
interaction	O
with	O
co	O
-	O
repressor	O
complexes	O
,	O
while	O
binding	O
to	O
5hmC	O
is	O
suggested	O
to	O
facilitate	O
gene	O
expression	O
through	O
the	O
organization	O
of	O
dynamic	O
chromatin	O
[	O
15	O
,	O
22	O
–	O
24	O
].	O

Research	O
studies	O
on	O
MeCP2	B-GP
have	O
shown	O
diverse	O
functions	O
of	O
this	O
protein	O
including	O
transcriptional	O
repression	O
,	O
transcriptional	O
activation	O
[	O
25	O
–	O
27	O
],	O
RNA	O
splicing	O
[	O
28	O
,	O
29	O
],	O
long	O
range	O
chromatin	O
remodeling	O
[	O
30	O
,	O
31	O
],	O
modulation	O
of	O
chromatin	O
architecture	O
,	O
and	O
maintenance	O
of	O
DNA	O
methylation	O
[	O
32	O
].	O

This	O
diversity	O
in	O
the	O
function	O
of	O
MeCP2	B-GP
underscores	O
its	O
role	O
in	O
many	O
disorders	O
.	O

MeCP2	B-GP
is	O
a	O
multifunctional	O
epigenetic	O
regulator	O
that	O
is	O
involved	O
in	O
transcriptional	O
regulation	O
as	O
well	O
as	O
modulating	O
chromatin	O
structure	O
[	O
17	O
,	O
33	O
].	O

Epigenetics	O
control	O
gene	O
expression	O
without	O
altering	O
the	O
corresponding	O
DNA	O
sequences	O
and	O
impact	O
development	O
and	O
disease	O
[	O
21	O
,	O
34	O
–	O
36	O
].	O

Epigenetic	O
mechanisms	O
control	O
the	O
expression	O
of	O
many	O
neurodevelopmentally	O
important	O
genes	O
through	O
chromatin	O
remodeling	O
,	O
histone	O
modifications	O
and	O
DNA	O
methylation	O
[	O
37	O
–	O
41	O
].	O

The	O
prevailing	O
view	O
of	O
MeCP2	B-GP
as	O
an	O
epigenetic	O
modulator	O
is	O
related	O
to	O
its	O
ability	O
to	O
associate	O
with	O
different	O
epigenetic	O
marks	O
(	O
either	O
through	O
direct	O
DNA	O
binding	O
or	O
recruiting	O
other	O
transcription	B-GP
factors	I-GP
).	O

Thus	O
,	O
MeCP2	B-GP
acts	O
as	O
an	O
‘	O
epigenetic	O
reader	O
’	O
that	O
contributes	O
in	O
the	O
establishment	O
of	O
functional	O
states	O
of	O
chromatin	O
structure	O
,	O
a	O
process	O
that	O
is	O
fundamental	O
for	O
normal	O
cellular	O
function	O
.	O

However	O
,	O
it	O
is	O
still	O
not	O
fully	O
understood	O
whether	O
MeCP2	B-GP
acts	O
as	O
a	O
genome	O
-	O
wide	O
epigenetic	O
regulator	O
or	O
as	O
a	O
gene	O
-	O
specific	O
transcriptional	O
modulator	O
,	O
and	O
evidence	O
exists	O
in	O
favor	O
of	O
both	O
mechanisms	O
[	O
15	O
,	O
42	O
].	O

MeCP2	B-GP
protein	O
is	O
highly	O
expressed	O
in	O
the	O
brain	O
compared	O
to	O
other	O
tissues	O
[	O
18	O
,	O
43	O
,	O
44	O
].	O

The	O
protein	O
expression	O
pattern	O
within	O
the	O
brain	O
follows	O
a	O
defined	O
pattern	O
,	O
with	O
early	O
appearing	O
structures	O
,	O
such	O
as	O
brainstem	O
and	O
thalamus	O
,	O
expressing	O
the	O
protein	O
before	O
more	O
rostral	O
structures	O
,	O
such	O
as	O
the	O
cortex	O
[	O
18	O
,	O
43	O
].	O

Temporally	O
,	O
MeCP2	B-GP
protein	O
expression	O
profile	O
is	O
low	O
at	O
birth	O
,	O
and	O
increases	O
dramatically	O
at	O
specific	O
time	O
periods	O
coinciding	O
with	O
the	O
process	O
of	O
neuronal	O
maturation	O
and	O
synaptogenesis	O
in	O
different	O
parts	O
of	O
the	O
brain	O
[	O
43	O
,	O
45	O
].	O

Cell	O
type	O
-	O
specific	O
studies	O
have	O
revealed	O
that	O
MeCP2	B-GP
levels	O
are	O
highest	O
in	O
mature	O
neurons	O
,	O
while	O
astrocytes	O
and	O
immature	O
neurons	O
express	O
lower	O
levels	O
of	O
MeCP2	B-GP
[	O
8	O
,	O
46	O
,	O
47	O
].	O

The	O
increased	O
levels	O
of	O
MeCP2	B-GP
expression	O
in	O
mature	O
neurons	O
are	O
maintained	O
throughout	O
adulthood	O
,	O
implying	O
a	O
requirement	O
for	O
postmitotic	O
neuronal	O
function	O
[	O
47	O
–	O
49	O
].	O

In	O
neurons	O
,	O
MeCP2	B-GP
is	O
involved	O
in	O
neuronal	O
maturation	O
,	O
dendrite	O
formation	O
,	O
and	O
synaptic	O
functions	O
[	O
15	O
,	O
49	O
,	O
50	O
].	O

Studies	O
of	O
mouse	B-OG
models	O
lacking	O
Mecp2	B-GP
expression	O
in	O
neurons	O
further	O
demonstrate	O
the	O
critical	O
role	O
of	O
MeCP2	B-GP
for	O
normal	O
brain	O
function	O
,	O
especially	O
with	O
regard	O
to	O
synaptic	O
modulation	O
and	O
maintenance	O
[	O
18	O
,	O
51	O
].	O

Most	O
MeCP2	B-GP
mutations	O
are	O
de	O
novo	O
and	O
can	O
be	O
grouped	O
into	O
three	O
general	O
categories	O
;	O
severe	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
,	O
mild	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
and	O
a	O
broad	O
group	O
of	O
duplications	O
and	O
other	O
non	O
-	O
coding	O
mutations	O
[	O
52	O
,	O
53	O
].	O

Each	O
category	O
of	O
mutation	O
is	O
associated	O
with	O
(	O
a	O
)	O
subset	O
(	O
s	O
)	O
of	O
neurological	O
symptoms	O
.	O

Genotype	O
-	O
phenotype	O
analyses	O
have	O
shown	O
that	O
there	O
is	O
no	O
direct	O
and	O
simple	O
correlation	O
with	O
the	O
type	O
of	O
observed	O
mutations	O
and	O
the	O
resulting	O
disease	O
phenotypes	O
.	O

The	O
difficulty	O
in	O
attributing	O
a	O
particular	O
type	O
of	O
mutation	O
to	O
a	O
specific	O
phenotype	O
might	O
be	O
in	O
part	O
due	O
to	O
the	O
pattern	O
of	O
X	O
-	O
chromosome	O
inactivation	O
(	O
XCI	O
)	O
[	O
54	O
,	O
55	O
].	O

Overall	O
,	O
MeCP2	B-GP
-	O
related	O
diseases	O
that	O
are	O
associated	O
with	O
protein	O
dysfunction	O
are	O
mainly	O
characterized	O
by	O
cognitive	B-DS
impairment	I-DS
and	O
intellectual	B-DS
disabilities	I-DS
[	O
33	O
].	O

However	O
,	O
dysregulation	O
of	O
the	O
protein	O
are	O
also	O
frequently	O
observed	O
in	O
cases	O
of	O
inherited	O
disorders	O
and	O
autoimmune	B-DS
diseases	I-DS
such	O
as	O
systemic	B-DS
lupus	I-DS
erythematosus	I-DS
(	O
SLE	B-DS
)	O
[	O
56	O
].	O

In	O
this	O
review	O
,	O
we	O
will	O
primarily	O
focus	O
on	O
human	B-OG
diseases	O
that	O
are	O
associated	O
with	O
MeCP2	B-GP
dysfunction	O
,	O
and	O
will	O
aim	O
to	O
highlight	O
the	O
role	O
of	O
MeCP2	B-GP
in	O
neurological	O
/	O
neuropsychiatric	O
and	O
non	O
-	O
neurological	B-DS
disorders	I-DS
.	O

In	O
addition	O
,	O
animal	B-OG
models	O
that	O
have	O
enabled	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
MeCP2	B-GP
action	O
will	O
be	O
discussed	O
.	O

2	O
.	O

The	O
Role	O
of	O
MeCP2	B-GP
in	O
Neurological	B-DS
Disorders	I-DS

2	O
.	O
1	O
.	O

Rett	B-DS
Syndrome	I-DS

Rett	B-DS
Syndrome	I-DS
(	O
RTT	B-DS
)	O
is	O
a	O
progressive	O
X	O
-	O
linked	O
neurological	B-DS
disorder	I-DS
that	O
mainly	O
affects	O
young	O
girls	O
with	O
an	O
incidence	O
rate	O
of	O
1	O
:	O
10	O
,	O
000	O
–	O
1	O
:	O
15	O
,	O
000	O
[	O
15	O
,	O
57	O
].	O

RTT	B-DS
is	O
,	O
perhaps	O
,	O
the	O
most	O
common	O
cause	O
of	O
mental	B-DS
retardation	I-DS
in	O
females	O
[	O
58	O
,	O
59	O
].	O

Although	O
it	O
was	O
initially	O
thought	O
to	O
occur	O
exclusively	O
in	O
females	O
,	O
males	O
have	O
also	O
been	O
identified	O
with	O
classic	O
RTT	B-DS
[	O
60	O
].	O

In	O
approximately	O
90	O
%	O
of	O
RTT	B-DS
cases	O
,	O
the	O
disease	O
is	O
due	O
to	O
MECP2	B-GP
gene	O
mutations	O
[	O
61	O
].	O
MECP2	B-GP
mutations	O
that	O
cause	O
classical	O
RTT	B-DS
in	O
females	O
typically	O
result	O
in	O
neonatal	B-DS
encephalopathy	I-DS
and	O
death	O
in	O
the	O
first	O
year	O
of	O
life	O
in	O
males	O
.	O

However	O
,	O
similar	O
MECP2	B-GP
mutations	O
may	O
result	O
in	O
RTT	B-DS
phenotypes	O
in	O
males	O
with	O
Kleinfelter	B-DS
syndrome	I-DS
(	O
47	O
,	O
XXY	O
),	O
or	O
somatic	O
mosaicism	O
[	O
62	O
,	O
63	O
].	O

There	O
is	O
the	O
classic	O
RTT	B-DS
as	O
well	O
as	O
atypical	O
forms	O
of	O
RTT	B-DS
that	O
deviate	O
from	O
the	O
classical	O
clinical	O
presentation	O
.	O

Classic	O
RTT	B-DS
is	O
noticed	O
primarily	O
during	O
infancy	O
and	O
can	O
be	O
divided	O
into	O
four	O
stages	O
that	O
reflect	O
the	O
characteristic	O
abnormalities	O
displayed	O
in	O
RTT	B-DS
patients	O
[	O
64	O
].	O

The	O
first	O
stage	O
takes	O
place	O
after	O
a	O
period	O
of	O
normal	O
development	O
,	O
during	O
the	O
first	O
6	O
–	O
18	O
months	O
after	O
birth	O
,	O
when	O
developmental	O
progression	O
ceases	O
and	O
acquisition	O
of	O
new	O
skills	O
is	O
delayed	O
.	O

General	O
motor	O
performance	O
such	O
as	O
crawling	O
,	O
sitting	O
,	O
and	O
walking	O
are	O
also	O
severely	O
impaired	O
at	O
this	O
stage	O
[	O
58	O
,	O
65	O
,	O
66	O
].	O

The	O
second	O
stage	O
of	O
RTT	B-DS
starts	O
at	O
approximately	O
one	O
to	O
four	O
years	O
,	O
with	O
developmental	O
stagnation	O
accompanied	O
by	O
general	O
growth	B-DS
retardation	I-DS
,	O
loss	O
of	O
purposeful	O
hand	O
movements	O
and	O
speech	O
,	O
tongue	O
protrusion	O
,	O
abnormal	O
facial	O
expression	O
,	O
weight	O
loss	O
,	O
and	O
gait	O
ataxia	B-DS
/	O
apraxia	B-DS
[	O
58	O
,	O
64	O
,	O
67	O
].	O

Autonomic	B-DS
dysfunction	I-DS
such	O
as	O
irregular	O
breathing	O
patterns	O
,	O
forced	O
expulsion	O
of	O
air	O
and	O
saliva	O
,	O
and	O
apnea	B-DS
can	O
also	O
be	O
observed	O
at	O
this	O
stage	O
[	O
68	O
].	O

The	O
duration	O
of	O
this	O
stage	O
is	O
from	O
weeks	O
to	O
approximately	O
a	O
year	O
.	O

The	O
third	O
RTT	B-DS
stage	O
is	O
regarded	O
as	O
a	O
relatively	O
‘	O
quiet	O
’	O
period	O
as	O
stabilization	O
of	O
some	O
of	O
the	O
symptoms	O
occurs	O
.	O

However	O
,	O
neuromotor	O
regression	O
and	O
stereotypic	O
hand	O
movements	O
still	O
persists	O
[	O
58	O
,	O
64	O
,	O
67	O
].	O

A	O
defining	O
feature	O
at	O
this	O
stage	O
is	O
the	O
occurrence	O
of	O
seizures	O
,	O
which	O
ranges	O
from	O
easily	O
controlled	O
to	O
intractable	B-DS
epilepsy	I-DS
[	O
69	O
].	O

The	O
duration	O
of	O
this	O
stage	O
is	O
usually	O
from	O
years	O
to	O
decades	O
[	O
67	O
].	O

The	O
last	O
RTT	B-DS
stage	O
takes	O
place	O
from	O
ages	O
5	O
–	O
15	O
years	O
and	O
beyond	O
.	O

Motor	O
deterioration	O
continues	O
and	O
results	O
in	O
loss	O
of	O
mobility	O
and	O
dependence	O
on	O
wheel	O
chair	O
.	O

Additional	O
abnormalities	O
include	O
dystonia	B-DS
,	O
severe	O
constipation	O
,	O
oropharyngeal	O
dysfunction	O
,	O
and	O
cardiac	O
abnormalities	O
[	O
68	O
].	O

As	O
patients	O
become	O
older	O
they	O
often	O
develop	O
Parkinson	O
’	O
s	O
-	O
like	O
features	O
[	O
64	O
,	O
68	O
].	O

The	O
duration	O
of	O
this	O
stage	O
varies	O
with	O
individuals	O
,	O
and	O
usually	O
lasts	O
for	O
decades	O
.	O

Atypical	O
forms	O
of	O
RTT	B-DS
deviate	O
from	O
classic	O
RTT	B-DS
with	O
respect	O
to	O
age	O
of	O
disease	O
onset	O
,	O
clinical	O
profile	O
and	O
severity	O
of	O
symptoms	O
.	O

These	O
forms	O
of	O
RTT	B-DS
occur	O
due	O
to	O
skewing	O
of	O
XCI	O
,	O
and	O
may	O
range	O
from	O
milder	O
forms	O
to	O
more	O
severe	O
manifestations	O
than	O
classic	O
RTT	B-DS
[	O
70	O
,	O
71	O
].	O

Mild	O
variants	O
of	O
RTT	B-DS
are	O
characterized	O
by	O
a	O
later	O
age	O
of	O
onset	O
,	O
typically	O
occurring	O
between	O
one	O
to	O
three	O
years	O
of	O
age	O
and	O
display	O
mild	O
stereotypic	O
movements	O
and	O
neurologic	O
symptoms	O
.	O

The	O
preserved	O
speech	O
or	O
the	O
Zappella	O
variant	O
is	O
a	O
mild	O
variant	O
of	O
RTT	B-DS
characterized	O
by	O
the	O
ability	O
of	O
patients	O
to	O
speak	O
a	O
few	O
words	O
.	O

Patients	O
with	O
this	O
variant	O
have	O
a	O
normal	O
head	O
size	O
and	O
are	O
usually	O
overweight	O
[	O
72	O
].	O

The	O
more	O
severe	O
variants	O
include	O
the	O
congenital	O
form	O
(	O
also	O
known	O
as	O
the	O
Rolando	O
variant	O
)	O
that	O
lack	O
the	O
early	O
period	O
of	O
normal	O
development	O
,	O
and	O
a	O
form	O
of	O
classical	O
RTT	B-DS
with	O
early	O
onset	O
seizures	O
before	O
the	O
age	O
of	O
six	O
months	O
(	O
also	O
known	O
as	O
the	O
Hanefeld	O
variant	O
)	O
[	O
73	O
,	O
74	O
].	O

Mutations	O
in	O
cyclin	B-GP
-	I-GP
dependent	I-GP
kinase	I-GP
-	I-GP
like	I-GP
5	I-GP
(	O
CDKL5	B-GP
)	O
are	O
associated	O
with	O
the	O
early	O
-	O
onset	O
seizure	O
variant	O
form	O
of	O
RTT	B-DS
,	O
while	O
mutations	O
in	O
forkhead	B-GP
box	I-GP
protein	I-GP
G1	I-GP
(	O
FOXG1	B-GP
)	O
are	O
associated	O
with	O
congenital	B-DS
RTT	I-DS
Syndrome	I-DS
variant	O
[	O
75	O
,	O
76	O
].	O

Magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
and	O
autopsy	O
examination	O
have	O
shown	O
that	O
major	O
morphological	O
abnormalities	O
detected	O
in	O
the	O
central	O
nervous	O
system	O
of	O
RTT	B-DS
patients	O
include	O
an	O
overall	O
decrease	O
in	O
the	O
size	O
of	O
the	O
brain	O
and	O
of	O
individual	O
neurons	O
[	O
77	O
].	O

The	O
reduction	O
in	O
brain	O
size	O
is	O
distributed	O
throughout	O
the	O
brain	O
and	O
affects	O
both	O
white	O
,	O
and	O
to	O
a	O
greater	O
extent	O
the	O
grey	O
matter	O
in	O
different	O
brain	O
regions	O
[	O
78	O
,	O
79	O
].	O

Cortical	O
and	O
cerebellar	O
degeneration	O
have	O
also	O
been	O
demonstrated	O
to	O
progressively	O
occur	O
with	O
increasing	O
age	O
in	O
RTT	B-DS
patients	O
[	O
80	O
].	O

2	O
.	O
2	O
.	O

MECP2	B-GP
Duplication	O
Disorder	O

MECP2	B-GP
duplication	O
syndrome	O
was	O
predicted	O
by	O
the	O
observation	O
that	O
mice	B-OG
engineered	O
to	O
overexpress	O
MECP2	B-GP
develop	O
a	O
progressive	O
neurological	B-DS
disorder	I-DS
including	O
stereotyped	O
and	O
repetitive	O
movements	O
,	O
epilepsy	B-DS
,	O
spasticity	O
,	O
hypoactivity	O
,	O
and	O
early	O
death	O
[	O
81	O
,	O
82	O
].	O

This	O
gain	O
of	O
function	O
mutation	O
occurs	O
mostly	O
in	O
males	O
[	O
83	O
].	O

Males	O
with	O
this	O
disorder	O
present	O
clinical	O
features	O
,	O
such	O
as	O
infantile	O
hypotonia	O
,	O
severe	O
to	O
profound	O
mental	B-DS
retardation	I-DS
,	O
poor	O
speech	O
development	O
,	O
recurrent	O
infections	B-DS
,	O
epilepsy	B-DS
,	O
and	O
progressive	O
spasticity	O
[	O
84	O
,	O
85	O
].	O

The	O
incidence	O
rate	O
of	O
MECP2	B-GP
duplication	O
disorder	O
is	O
estimated	O
to	O
be	O
1	O
%	O
of	O
unexplained	O
X	O
-	O
linked	O
diseases	O
and	O
most	O
of	O
the	O
reported	O
cases	O
are	O
inherited	O
[	O
86	O
].	O

However	O
,	O
de	O
novo	O
cases	O
have	O
also	O
been	O
documented	O
[	O
87	O
].	O

There	O
is	O
considerable	O
clinical	O
overlap	O
in	O
patients	O
with	O
classic	O
RTT	B-DS
and	O
MECP2	B-GP
duplication	O
disorder	O
specifically	O
in	O
behavioral	O
phenotypes	O
,	O
such	O
as	O
stereotypic	O
hand	O
/	O
body	O
movements	O
,	O
anxiety	O
,	O
and	O
social	O
avoidance	O
[	O
88	O
].	O

However	O
,	O
in	O
contrast	O
to	O
RTT	B-DS
,	O
immunodeficiency	O
is	O
observed	O
in	O
patients	O
with	O
MECP2	B-GP
duplication	O
disorder	O
.	O

It	O
remains	O
unclear	O
if	O
this	O
phenotype	O
occurs	O
due	O
to	O
secondary	O
effects	O
from	O
increased	O
dosage	O
of	O
MeCP2	B-GP
protein	O
[	O
89	O
].	O

Approximately	O
40	O
%	O
of	O
males	O
with	O
MECP2	B-GP
duplication	O
reported	O
so	O
far	O
have	O
died	O
before	O
their	O
25th	O
birthday	O
,	O
usually	O
from	O
respiratory	B-DS
infections	I-DS
[	O
90	O
].	O

2	O
.	O
3	O
.	O

Angelman	B-DS
Syndrome	I-DS

MECP2	B-GP
mutations	O
that	O
cause	O
RTT	B-DS
have	O
also	O
been	O
reported	O
in	O
cases	O
of	O
Angelman	B-DS
Syndrome	I-DS
(	O
AS	B-DS
)	O
[	O
91	O
–	O
93	O
].	O

Angelman	B-DS
Syndrome	I-DS
is	O
primarily	O
caused	O
by	O
mutations	O
or	O
imprinting	O
errors	O
of	O
the	O
UBE3A	B-GP
gene	O
located	O
on	O
chromosome	O
15	O
,	O
and	O
is	O
characterized	O
by	O
intellectual	B-DS
disability	I-DS
;	O
severe	O
speech	O
impairment	O
and	O
gait	O
ataxia	B-DS
.	O

Considerable	O
phenotypic	O
overlap	O
exists	O
between	O
AS	B-DS
and	O
RTT	B-DS
;	O
however	O
they	O
differ	O
with	O
respect	O
to	O
timing	O
of	O
symptom	O
onset	O
.	O

Angelman	B-DS
Syndrome	I-DS
has	O
an	O
earlier	O
onset	O
and	O
patients	O
are	O
characterized	O
with	O
low	O
hypotonicity	O
at	O
birth	O
[	O
91	O
].	O

2	O
.	O
4	O
.	O

X	O
-	O
linked	O
Mental	B-DS
Retardation	I-DS

X	O
-	O
linked	O
mental	B-DS
retardation	I-DS
(	O
XLMR	O
)	O
is	O
a	O
genetic	B-DS
disorder	I-DS
arising	O
from	O
mutations	O
or	O
duplication	O
of	O
genes	O
across	O
the	O
X	O
chromosome	O
,	O
including	O
the	O
MECP2	B-GP
gene	O
.	O
MECP2	B-GP
point	O
mutations	O
have	O
been	O
identified	O
in	O
up	O
to	O
2	O
%	O
of	O
individuals	O
with	O
XLMR	O
and	O
duplications	O
of	O
the	O
gene	O
are	O
also	O
implicated	O
in	O
approximately	O
1	O
%	O
to	O
2	O
%	O
of	O
XLMR	O
cases	O
[	O
86	O
,	O
94	O
].	O
MECP2	B-GP
mutations	O
that	O
cause	O
RTT	B-DS
or	O
severe	O
neonatal	B-DS
encephalopathy	I-DS
are	O
not	O
identified	O
in	O
XLMR	O
patients	O
and	O
vice	O
versa	O
[	O
86	O
,	O
95	O
].	O

In	O
addition	O
,	O
the	O
molecular	O
lesions	O
underlying	O
MECP2	B-GP
duplications	O
that	O
result	O
in	O
XLMR	O
are	O
different	O
from	O
those	O
observed	O
in	O
MECP2	B-GP
duplication	O
syndrome	O
[	O
96	O
].	O

Males	O
with	O
XLMR	O
show	O
phenotypes	O
,	O
such	O
as	O
severe	O
intellectual	B-DS
disability	I-DS
,	O
speech	O
impairment	O
,	O
and	O
motor	O
abnormalities	O
,	O
whereas	O
females	O
display	O
mild	O
intellectual	B-DS
disability	I-DS
or	O
are	O
unaffected	O
[	O
86	O
].	O

2	O
.	O
5	O
.	O

Severe	O
Neonatal	B-DS
Encephalopathy	I-DS

Males	O
with	O
a	O
normal	O
karyotype	O
and	O
a	O
mutation	O
in	O
the	O
MECP2	B-GP
gene	O
present	O
with	O
a	O
distinct	O
clinical	O
condition	O
,	O
and	O
severe	O
neonatal	B-DS
encephalopathy	I-DS
(	O
SNE	O
)	O
[	O
97	O
].	O

Severe	O
neonatal	B-DS
encephalopathy	I-DS
is	O
a	O
disorder	O
characterized	O
by	O
a	O
static	B-DS
encephalopathy	I-DS
,	O
severe	O
developmental	O
delays	O
and	O
respiratory	O
abnormalities	O
.	O

The	O
mutations	O
are	O
usually	O
inherited	O
from	O
mothers	O
with	O
favorable	O
XCI	O
skewing	O
that	O
display	O
mild	O
/	O
no	O
RTT	B-DS
symptoms	O
.	O

Males	O
with	O
SNE	O
often	O
die	O
within	O
the	O
first	O
years	O
of	O
their	O
life	O
due	O
to	O
autonomic	B-DS
dysfunction	I-DS
[	O
95	O
,	O
98	O
].	O

Some	O
MECP2	B-GP
mutations	O
that	O
do	O
not	O
cause	O
RTT	B-DS
in	O
females	O
have	O
also	O
been	O
implicated	O
in	O
moderate	O
to	O
profound	O
mental	B-DS
retardation	I-DS
,	O
deficits	O
in	O
language	O
and	O
motor	O
skills	O
,	O
obesity	B-DS
,	O
autistic	O
features	O
,	O
and	O
psychiatric	B-DS
disorders	I-DS
in	O
males	O
[	O
54	O
].	O

2	O
.	O
6	O
.	O

Autism	B-DS

Autism	B-DS
and	O
RTT	B-DS
are	O
similar	O
developmental	B-DS
disorders	I-DS
that	O
belong	O
to	O
the	O
spectrum	O
of	O
autism	B-DS
disorders	I-DS
classified	O
as	O
pervasive	B-DS
developmental	I-DS
disorders	I-DS
,	O
or	O
Autism	B-DS
Spectrum	I-DS
Disorders	I-DS
(	O
ASD	B-DS
)	O
[	O
99	O
].	O

Although	O
they	O
are	O
similar	O
developmental	B-DS
disorders	I-DS
,	O
autism	B-DS
differs	O
from	O
RTT	B-DS
with	O
respect	O
to	O
its	O
genetic	O
basis	O
.	O

While	O
RTT	B-DS
is	O
caused	O
by	O
MECP2	B-GP
mutations	O
,	O
the	O
genetic	O
basis	O
of	O
autism	B-DS
is	O
not	O
fully	O
clear	O
and	O
is	O
proposed	O
to	O
involve	O
multiple	O
genes	O
[	O
100	O
].	O

Mutations	O
in	O
the	O
MECP2	B-GP
regulatory	O
elements	O
(	O
resulting	O
in	O
decreased	O
expression	O
of	O
the	O
protein	O
)	O
are	O
commonly	O
associated	O
with	O
autism	B-DS
[	O
101	O
].	O

Reduced	O
expression	O
of	O
MeCP2	B-GP
protein	O
has	O
been	O
shown	O
to	O
occur	O
frequently	O
in	O
the	O
frontal	O
cortex	O
of	O
autistic	O
patients	O
and	O
is	O
correlated	O
with	O
increased	O
MECP2	B-GP
promoter	O
DNA	O
methylation	O
[	O
102	O
].	O

The	O
silencing	O
of	O
autism	B-DS
-	O
related	O
genes	O
through	O
promoter	O
DNA	O
hypermethylation	O
is	O
commonly	O
associated	O
with	O
autism	B-DS
,	O
and	O
drugs	O
that	O
can	O
demethylate	O
promoters	O
might	O
be	O
useful	O
in	O
activating	O
these	O
genes	O
[	O
103	O
,	O
104	O
].	O

In	O
a	O
recent	O
study	O
,	O
we	O
show	O
that	O
reduced	O
DNA	O
demethylation	O
at	O
the	O
Mecp2	B-GP
promoter	O
and	O
intron	O
1	O
regulatory	O
elements	O
treated	O
with	O
Decitabine	O
is	O
associated	O
with	O
increased	O
Mecp2	B-GP
expression	O
.	O

Our	O
results	O
provide	O
insight	O
on	O
use	O
of	O
such	O
drugs	O
for	O
future	O
therapeutic	O
interventions	O
of	O
autism	B-DS
[	O
105	O
].	O

Moreover	O
,	O
MECP2	B-GP
mutations	O
that	O
are	O
associated	O
with	O
classic	O
RTT	B-DS
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
autistic	O
females	O
who	O
do	O
not	O
meet	O
the	O
diagnostic	O
criteria	O
for	O
RTT	B-DS
[	O
100	O
].	O

This	O
makes	O
it	O
difficult	O
to	O
determine	O
if	O
a	O
MECP2	B-GP
mutation	O
that	O
is	O
associated	O
with	O
autism	B-DS
diagnosis	O
is	O
a	O
different	O
disorder	O
from	O
RTT	B-DS
,	O
or	O
if	O
both	O
disorders	O
are	O
simply	O
different	O
representations	O
on	O
a	O
spectrum	O
associated	O
with	O
MECP2	B-GP
mutations	O
.	O
MECP2	B-GP
mutations	O
have	O
also	O
been	O
reported	O
in	O
patients	O
with	O
mild	O
cognitive	O
and	O
motor	O
difficulties	O
and	O
early	B-DS
-	I-DS
onset	I-DS
schizophrenia	I-DS
[	O
106	O
].	O

2	O
.	O
7	O
.	O

Fetal	B-DS
Alcohol	I-DS
Spectrum	I-DS
Disorders	I-DS

Prenatal	O
exposure	O
to	O
alcohol	O
is	O
associated	O
with	O
adverse	O
effects	O
on	O
neurodevelopment	O
,	O
and	O
results	O
in	O
a	O
set	O
of	O
severe	O
neurodevelopmental	B-DS
disorders	I-DS
known	O
as	O
fetal	B-DS
alcohol	I-DS
spectrum	I-DS
disorders	I-DS
(	O
FASD	B-DS
)	O
[	O
107	O
,	O
108	O
].	O

The	O
incidence	O
of	O
FASD	B-DS
is	O
estimated	O
to	O
be	O
as	O
high	O
as	O
1	O
in	O
100	O
births	O
and	O
this	O
disorder	O
commonly	O
manifests	O
as	O
cognitive	O
and	O
intellectual	B-DS
disabilities	I-DS
[	O
108	O
].	O

Accumulating	O
evidence	O
-	O
implicating	O
MeCP2	B-GP
in	O
FASD	B-DS
pathogenesis	O
further	O
reinforces	O
the	O
critical	O
role	O
of	O
MeCP2	B-GP
for	O
central	O
nervous	O
system	O
function	O
.	O

Several	O
studies	O
have	O
demonstrated	O
aberrant	O
expression	O
levels	O
of	O
MeCP2	B-GP
in	O
rodent	O
FASD	B-DS
models	O
,	O
and	O
this	O
is	O
suggested	O
to	O
be	O
an	O
important	O
epigenetic	O
determinant	O
in	O
FASD	B-DS
[	O
109	O
,	O
110	O
].	O

For	O
example	O
,	O
prenatal	O
exposure	O
to	O
ethanol	O
has	O
been	O
demonstrated	O
to	O
significantly	O
decrease	O
MeCP2	B-GP
expression	O
in	O
both	O
prefrontal	O
cortex	O
and	O
striatum	O
of	O
rodent	O
offspring	O
[	O
109	O
].	O

Research	O
in	O
animal	B-OG
models	O
suggests	O
that	O
the	O
global	O
epigenetic	O
changes	O
due	O
to	O
ethanol	O
are	O
related	O
to	O
variations	O
in	O
the	O
levels	O
,	O
duration	O
as	O
well	O
as	O
time	O
of	O
exposure	O
[	O
108	O
,	O
111	O
].	O

Further	O
supporting	O
the	O
potential	O
role	O
of	O
MeCP2	B-GP
in	O
FASD	B-DS
,	O
RTT	B-DS
-	O
causing	O
mutations	O
have	O
been	O
reported	O
in	O
a	O
FASD	B-DS
patient	O
[	O
112	O
].	O

MeCP2	B-GP
has	O
been	O
also	O
shown	O
to	O
modulate	O
the	O
alcohol	O
intake	O
and	O
sensitivity	O
to	O
alcohol	O
,	O
demonstrating	O
the	O
role	O
of	O
MeCP2	B-GP
in	O
alcoholism	B-DS
[	O
113	O
].	O

2	O
.	O
8	O
.	O

Huntington	B-DS
’	I-DS
s	I-DS
Disease	I-DS

Huntington	B-DS
’	I-DS
s	I-DS
disease	I-DS
(	O
HD	B-DS
)	O
is	O
a	O
progressive	O
neurodegenerative	B-DS
disorder	I-DS
that	O
affects	O
muscle	O
coordination	O
and	O
results	O
in	O
cognitive	B-DS
decline	I-DS
and	O
psychiatric	B-DS
disorders	I-DS
[	O
114	O
,	O
115	O
].	O

It	O
is	O
one	O
of	O
several	O
tri	O
-	O
nucleotide	O
repeat	O
disorders	O
caused	O
by	O
the	O
length	O
of	O
a	O
repeated	O
section	O
of	O
a	O
gene	O
exceeding	O
a	O
normal	O
range	O
.	O

Expansion	O
of	O
a	O
CAG	O
triplet	O
repeat	O
stretch	O
within	O
the	O
Huntingtin	B-GP
gene	O
(	O
HTT	B-GP
)	O
results	O
in	O
a	O
mutant	O
form	O
of	O
the	O
protein	O
,	O
which	O
gradually	O
damages	O
brain	O
cells	O
[	O
114	O
,	O
116	O
].	O

Transcriptional	O
dysregulation	O
has	O
been	O
suggested	O
to	O
play	O
major	O
roles	O
in	O
HD	B-DS
pathology	O
,	O
and	O
it	O
was	O
recently	O
demonstrated	O
that	O
the	O
huntingtin	B-GP
protein	O
(	O
Htt	B-GP
)	O
directly	O
interacts	O
with	O
MeCP2	B-GP
in	O
mouse	B-OG
and	O
cellular	O
models	O
of	O
HD	B-DS
.	O

Aberrant	O
interactions	O
between	O
Htt	B-GP
and	O
MeCP2	B-GP
is	O
suggested	O
to	O
contribute	O
to	O
aberrant	O
transcription	O
in	O
Huntington	B-DS
’	I-DS
s	I-DS
disease	I-DS
by	O
regulating	O
brain	B-GP
-	I-GP
derived	I-GP
neurotrophic	I-GP
factor	I-GP
(	O
BDNF	B-GP
)	O
levels	O
[	O
117	O
].	O

The	O
implication	O
of	O
MeCP2	B-GP
in	O
such	O
diverse	O
range	O
of	O
neurological	B-DS
disorders	I-DS
necessitates	O
a	O
complete	O
understanding	O
of	O
its	O
relationship	O
to	O
brain	O
development	O
and	O
function	O
,	O
as	O
well	O
as	O
its	O
interaction	O
with	O
other	O
epigenetic	O
factors	O
that	O
mediate	O
dysregulation	O
of	O
normal	O
epigenetic	O
program	O
of	O
the	O
brain	O
.	O

3	O
.	O

Non	O
-	O
Neurological	B-DS
Disorders	I-DS
Associated	O
with	O
MeCP2	B-GP

3	O
.	O
1	O
.	O

Cancer	B-DS

Apart	O
from	O
to	O
its	O
role	O
in	O
neurological	B-DS
disorders	I-DS
,	O
MeCP2	B-GP
has	O
also	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
many	O
cancers	B-DS
such	O
as	O
breast	O
,	O
colorectal	O
,	O
lung	O
,	O
liver	O
,	O
and	O
prostate	B-DS
cancer	I-DS
[	O
118	O
–	O
123	O
].	O

MeCP2	B-GP
role	O
in	O
cancer	B-DS
is	O
related	O
to	O
the	O
epigenetic	O
regulation	O
of	O
cancer	B-DS
-	O
related	O
genes	O
,	O
particularly	O
mechanisms	O
that	O
involve	O
hypermethylation	O
of	O
gene	O
promoters	O
[	O
118	O
].	O

The	O
growth	O
-	O
promoting	O
role	O
of	O
MeCP2	B-GP
in	O
prostate	B-DS
cancer	I-DS
cells	O
has	O
been	O
demonstrated	O
previously	O
,	O
where	O
it	O
was	O
shown	O
to	O
control	O
mechanisms	O
,	O
such	O
as	O
cell	O
proliferation	O
and	O
apoptosis	O
[	O
119	O
].	O

In	O
gastric	B-DS
cancer	I-DS
,	O
the	O
depth	O
of	O
invasion	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
MeCP2	B-GP
protein	O
levels	O
.	O

In	O
gastric	B-DS
carcinoma	I-DS
cells	O
,	O
microRNA	O
miR	O
-	O
212	O
was	O
shown	O
to	O
suppress	O
translation	O
of	O
MECP2	B-GP
transcripts	O
,	O
which	O
in	O
turn	O
resulted	O
in	O
reduced	O
depth	O
of	O
cellular	O
invasion	O
[	O
124	O
].	O

In	O
addition	O
,	O
MeCP2	B-GP
has	O
been	O
linked	O
to	O
other	O
cancers	B-DS
,	O
such	O
as	O
myeloma	B-DS
[	O
125	O
],	O
hematological	B-DS
malignancies	I-DS
[	O
126	O
],	O
ductal	B-DS
carcinomas	I-DS
[	O
127	O
],	O
and	O
cervical	B-DS
cancers	I-DS
[	O
128	O
].	O

3	O
.	O
2	O
.	O

Systemic	B-DS
Lupus	I-DS
Erythematosus	I-DS

Systemic	B-DS
lupus	I-DS
erythematosus	I-DS
(	O
SLE	B-DS
)	O
is	O
a	O
systemic	B-DS
autoimmune	I-DS
disease	I-DS
that	O
affects	O
multiple	O
organs	O
.	O

The	O
disease	O
predominantly	O
affects	O
females	O
,	O
with	O
a	O
female	O
to	O
male	O
ratio	O
that	O
ranges	O
from	O
4	O
.	O
3	O
–	O
13	O
.	O
6	O
to	O
1	O
[	O
56	O
,	O
129	O
].	O

Although	O
the	O
cause	O
of	O
SLE	B-DS
is	O
still	O
not	O
clear	O
,	O
evidence	O
supports	O
an	O
important	O
role	O
for	O
abnormal	O
T	O
cell	O
DNA	O
methylation	O
in	O
the	O
pathogenesis	O
of	O
SLE	B-DS
,	O
as	O
methylation	O
sensitive	O
genes	O
show	O
increased	O
expression	O
in	O
T	O
cells	O
of	O
SLE	B-DS
patients	O
[	O
130	O
].	O

In	O
active	O
SLE	B-DS
T	O
-	O
cells	O
,	O
the	O
expression	O
of	O
DNA	B-GP
methyltransferase	I-GP
1	I-GP
(	O
DNMT1	B-GP
),	O
the	O
main	O
enzyme	O
that	O
maintains	O
DNA	O
methylation	O
during	O
cell	O
division	O
,	O
is	O
reduced	O
,	O
resulting	O
in	O
promoter	O
hypomethylation	O
of	O
these	O
methylation	O
-	O
sensitive	O
genes	O
[	O
56	O
,	O
131	O
,	O
132	O
].	O

MeCP2	B-GP
is	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
this	O
process	O
as	O
it	O
is	O
critical	O
for	O
the	O
epigenetic	O
regulation	O
of	O
methylation	O
-	O
sensitive	O
genes	O
,	O
and	O
genetic	O
polymorphisms	O
in	O
MECP2	B-GP
have	O
also	O
been	O
identified	O
in	O
patients	O
with	O
SLE	B-DS
[	O
56	O
,	O
133	O
,	O
134	O
].	O

Moreover	O
,	O
MeCP2	B-GP
associates	O
with	O
DNMT1	B-GP
,	O
the	O
association	O
of	O
which	O
is	O
required	O
to	O
maintain	O
DNA	O
methylation	O
[	O
32	O
].	O

The	O
association	O
between	O
MeCP2	B-GP
,	O
DNMT	B-GP
,	O
and	O
methylation	O
-	O
sensitive	O
genes	O
suggests	O
an	O
important	O
role	O
for	O
epigenetic	O
regulation	O
in	O
the	O
pathogenesis	O
of	O
SLE	B-DS
and	O
other	O
autoimmune	B-DS
diseases	I-DS
.	O

3	O
.	O
3	O
.	O

Rheumatoid	B-DS
Arthritis	I-DS

Rheumatoid	B-DS
arthritis	I-DS
(	O
RA	B-DS
)	O
is	O
a	O
systemic	B-DS
autoimmune	I-DS
disease	I-DS
that	O
results	O
in	O
chronic	O
inflammation	O
and	O
destruction	O
of	O
many	O
tissues	O
and	O
organs	O
,	O
primarily	O
flexible	O
synovial	O
joints	O
[	O
135	O
–	O
137	O
].	O

It	O
is	O
characterized	O
by	O
the	O
presence	O
of	O
auto	O
antibodies	O
,	O
which	O
may	O
be	O
detected	O
in	O
the	O
blood	O
long	O
before	O
the	O
onset	O
of	O
disease	O
[	O
138	O
,	O
139	O
].	O

Increasing	O
evidence	O
suggests	O
that	O
DNA	O
methylation	O
and	O
histone	O
modifications	O
regulate	O
the	O
progression	O
of	O
Rheumatoid	B-DS
arthritis	I-DS
.	O

Interestingly	O
,	O
it	O
has	O
been	O
shown	O
that	O
MeCP2	B-GP
expression	O
levels	O
were	O
up	O
-	O
regulated	O
in	O
rodent	O
models	O
of	O
RA	B-DS
,	O
and	O
it	O
is	O
hypothesized	O
that	O
the	O
increased	O
MeCP2	B-GP
protein	O
levels	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
RA	B-DS
through	O
the	O
canonical	O
Wnt	O
pathway	O
[	O
140	O
,	O
141	O
].	O

3	O
.	O
4	O
.	O

Hirschsprung	B-DS
’	I-DS
s	I-DS
Disease	I-DS

Hirschsprung	B-DS
’	I-DS
s	I-DS
disease	I-DS
(	O
HSCR	B-DS
)	O
is	O
a	O
congenital	B-DS
disorder	I-DS
of	O
the	O
colon	O
characterized	O
by	O
the	O
absence	O
of	O
certain	O
nerve	O
cells	O
known	O
as	O
ganglion	O
cells	O
[	O
142	O
,	O
143	O
].	O

The	O
incidence	O
of	O
HSCR	B-DS
is	O
about	O
1	O
:	O
2000	O
–	O
5000	O
,	O
with	O
males	O
being	O
affected	O
4	O
times	O
more	O
frequently	O
than	O
females	O
[	O
144	O
].	O

The	O
lack	O
of	O
ganglion	O
cells	O
is	O
associated	O
with	O
impaired	O
craniocaudal	O
migration	O
of	O
neural	O
crest	O
cells	O
,	O
and	O
results	O
in	O
severe	O
constipation	O
or	O
intestinal	B-DS
obstruction	I-DS
[	O
145	O
,	O
146	O
].	O

Defects	O
in	O
the	O
differentiation	O
of	O
neuroblasts	O
into	O
ganglion	O
cells	O
may	O
also	O
contribute	O
to	O
the	O
disorder	O
[	O
142	O
].	O

A	O
recent	O
study	O
implicating	O
MeCP2	B-GP
in	O
the	O
pathogenesis	O
of	O
HSCR	B-DS
suggests	O
that	O
aberrant	O
reduced	O
levels	O
of	O
MeCP2	B-GP
may	O
play	O
an	O
important	O
role	O
in	O
suppressing	O
the	O
proliferative	O
ability	O
of	O
cells	O
in	O
patients	O
with	O
Hirschsprung	B-DS
’	I-DS
s	I-DS
disease	I-DS
[	O
147	O
].	O
Table	O
1	O
represents	O
a	O
list	O
of	O
MeCP2	B-GP
-	O
associated	O
diseases	O
and	O
the	O
genders	O
that	O
are	O
mostly	O
affected	O
.	O

4	O
.	O

Animal	B-OG
Models	O
of	O
MeCP2	B-GP
Dysfunction	O

Several	O
animal	B-OG
models	O
have	O
been	O
generated	O
in	O
order	O
to	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
,	O
progression	O
and	O
pathology	O
of	O
disorders	O
that	O
are	O
associated	O
with	O
MeCP2	B-GP
dysfunction	O
.	O

These	O
include	O
mostly	O
rodent	O
models	O
(	O
particularly	O
mouse	B-OG
models	O
)	O
as	O
well	O
as	O
zebrafish	B-OG
and	O
Drosophila	B-OG
models	O
.	O

Different	O
strategies	O
are	O
often	O
employed	O
to	O
alter	O
the	O
expression	O
and	O
function	O
of	O
MeCP2	B-GP
in	O
these	O
animal	B-OG
models	O
.	O

4	O
.	O
1	O
.	O

Mecp2	B-GP
Null	O
Mouse	B-OG
Models	O

Mecp2	B-GP
knockout	O
mice	B-OG
have	O
been	O
generated	O
using	O
the	O
Cre	B-GP
recombinase	I-GP
-	O
loxP	O
system	O
.	O

These	O
mice	B-OG
appear	O
normal	O
until	O
approximately	O
three	O
to	O
four	O
weeks	O
of	O
age	O
,	O
when	O
they	O
begin	O
to	O
exhibit	O
behavioral	O
phenotypes	O
such	O
as	O
unusual	O
gait	O
,	O
hindlimb	O
clasping	O
,	O
seizures	O
,	O
tremors	O
,	O
anxiety	O
,	O
learning	O
and	O
memory	O
deficits	O
,	O
and	O
irregular	O
breathing	O
.	O

Brain	O
neuropathology	O
observed	O
in	O
Mecp2	B-GP
knockout	O
mice	B-OG
is	O
similar	O
to	O
that	O
observed	O
in	O
RTT	B-DS
individuals	O
.	O
Mecp2	B-GP
knockout	O
mice	B-OG
have	O
smaller	O
densely	O
packed	O
neurons	O
,	O
reduced	O
dendritic	O
spine	O
density	O
,	O
deficits	O
in	O
axonal	O
fasciculation	O
and	O
reduced	O
number	O
of	O
mature	O
synapses	O
.	O
Mecp2	B-GP
knockout	O
mice	B-OG
die	O
at	O
approximately	O
10	O
weeks	O
of	O
life	O
[	O
150	O
–	O
152	O
].	O

The	O
reactivation	O
of	O
Mecp2	B-GP
in	O
the	O
brains	O
of	O
Mecp2	B-GP
null	O
mice	B-OG
rescued	O
many	O
RTT	B-DS
-	O
phenotypes	O
seen	O
in	O
the	O
null	O
mice	B-OG
,	O
including	O
delayed	O
disease	O
progression	O
,	O
increased	O
life	O
span	O
,	O
deceased	O
mortality	O
,	O
and	O
restored	O
neurological	O
functions	O
[	O
153	O
,	O
154	O
].	O

4	O
.	O
2	O
.	O

Mecp2	B-GP
Mutant	O
Mice	B-OG

Mecp2	B-GP
mutant	O
mice	B-OG
differ	O
from	O
the	O
above	O
-	O
mentioned	O
knockout	O
mice	B-OG
as	O
they	O
express	O
a	O
truncated	O
/	O
mutant	O
MeCP2	B-GP
protein	O
.	O

One	O
of	O
such	O
mutant	O
mice	B-OG
is	O
the	O
Jaenisch	O
strain	O
(	O
Mecp2tm1	O
.	O
1jae	O
),	O
generated	O
by	O
deletion	O
of	O
exon	O
3	O
of	O
the	O
Mecp2	B-GP
gene	O
.	O

Jaenisch	O
mice	B-OG
display	O
behavioral	O
phenotypes	O
similar	O
to	O
the	O
Mecp2	B-GP
knockout	O
mice	B-OG
,	O
although	O
the	O
phenotype	O
is	O
slightly	O
milder	O
and	O
the	O
lifespan	O
is	O
longer	O
(	O
12	O
weeks	O
)	O
[	O
82	O
,	O
155	O
].	O

Another	O
Mecp2	B-GP
mutant	O
mouse	B-OG
model	O
has	O
been	O
generated	O
that	O
expresses	O
a	O
protein	O
truncated	O
at	O
amino	O
acid	O
308	O
(	O
Mecp2308	O
).	O

It	O
is	O
assumed	O
that	O
the	O
truncated	O
MeCP2	B-GP
protein	O
produced	O
in	O
these	O
mice	B-OG
has	O
residual	O
unknown	O
functions	O
.	O
Mecp2308	O
mice	B-OG
appear	O
normal	O
until	O
approximately	O
six	O
weeks	O
of	O
age	O
when	O
they	O
develop	O
similar	O
but	O
milder	O
neurological	O
phenotype	O
as	O
Mecp2	B-GP
knockout	O
mice	B-OG
[	O
156	O
].	O

4	O
.	O
3	O
.	O

Mecp2	B-GP
Conditional	O
-	O
Mutant	O
Mice	B-OG

Brain	O
-	O
specific	O
deletion	O
of	O
Mecp2	B-GP
in	O
neural	O
precursor	O
cells	O
,	O
beginning	O
at	O
embryonic	O
day	O
12	O
(	O
Nestin	B-GP
-	O
cre	B-GP
line	O
),	O
results	O
in	O
mice	B-OG
that	O
display	O
phenotypes	O
similar	O
to	O
Mecp2	B-GP
knockout	O
mice	B-OG
[	O
150	O
,	O
155	O
].	O

This	O
suggests	O
that	O
MeCP2	B-GP
dysfunction	O
in	O
the	O
CNS	O
is	O
sufficient	O
to	O
cause	O
phenotypes	O
observed	O
in	O
RTT	B-DS
.	O

Selective	O
loss	O
of	O
Mecp2	B-GP
in	O
hypothalamic	O
and	O
amygdala	O
neurons	O
(	O
Sim1	B-GP
-	O
cre	B-GP
line	O
)	O
results	O
in	O
mice	B-OG
that	O
display	O
similar	O
abnormal	O
physiological	O
stress	O
response	O
as	O
that	O
observed	O
in	O
brain	O
-	O
specific	O
conditional	O
mice	B-OG
.	O

These	O
mice	B-OG
were	O
also	O
obese	O
and	O
aggressive	O
,	O
suggesting	O
a	O
role	O
for	O
MeCP2	B-GP
in	O
regulating	O
social	O
and	O
feeding	O
behaviors	O
[	O
157	O
].	O

Deletion	O
of	O
Mecp2	B-GP
in	O
other	O
parts	O
of	O
the	O
brain	O
such	O
as	O
in	O
brainstem	O
neurons	O
(	O
TH	B-GP
-	O
cre	B-GP
line	O
)	O
significantly	O
affects	O
locomotor	O
activity	O
,	O
with	O
no	O
effect	O
on	O
social	O
interaction	O
,	O
breathing	O
patterns	O
,	O
learning	O
and	O
memory	O
[	O
158	O
,	O
159	O
].	O

4	O
.	O
4	O
.	O

Mice	B-OG
Overexpressing	O
MECP2	B-GP

Mice	B-OG
overexpressing	O
human	B-OG
MECP2	B-GP
at	O
approximately	O
twice	O
the	O
endogenous	O
levels	O
exhibit	O
delayed	O
neurological	O
symptoms	O
at	O
approximately	O
10	O
weeks	O
.	O

These	O
symptoms	O
include	O
enhanced	O
motor	O
learning	O
and	O
synaptic	O
plasticity	O
in	O
the	O
hippocampus	O
.	O

However	O
at	O
20	O
weeks	O
,	O
these	O
mice	B-OG
develop	O
seizures	O
and	O
become	O
hypoactive	O
and	O
the	O
majority	O
of	O
them	O
die	O
by	O
approximately	O
one	O
year	O
of	O
age	O
[	O
81	O
].	O

Increased	O
MeCP2	B-GP
expression	O
in	O
other	O
transgenic	O
lines	O
also	O
results	O
in	O
motor	O
abnormalities	O
and	O
neurological	O
symptoms	O
[	O
160	O
].	O

These	O
transgenic	O
mice	B-OG
mimic	O
MECP2	B-GP
duplication	O
syndrome	O
that	O
is	O
observed	O
in	O
humans	B-OG
,	O
and	O
reinforces	O
the	O
notion	O
of	O
a	O
critical	O
requirement	O
for	O
precise	O
dosage	O
of	O
MeCP2	B-GP
protein	O
.	O

4	O
.	O
5	O
.	O

Mouse	B-OG
Models	O
Carrying	O
Rett	B-DS
Syndrome	I-DS
-	O
Associated	O
Mutations	O

A	O
mouse	B-OG
model	O
of	O
Rett	B-DS
syndrome	I-DS
was	O
generated	O
by	O
introducing	O
a	O
premature	O
STOP	O
codon	O
at	O
the	O
amino	O
acid	O
position	O
168	O
,	O
and	O
resulted	O
in	O
a	O
truncated	O
MeCP2	B-GP
protein	O
(	O
Mecp2R168X	O
).	O

These	O
mice	B-OG
display	O
neurological	O
phenotypes	O
such	O
as	O
hind	O
limb	O
clasping	O
and	O
breathing	O
irregularities	O
similar	O
to	O
other	O
mouse	B-OG
models	O
[	O
161	O
].	O

Another	O
RTT	B-DS
mouse	B-OG
model	O
is	O
the	O
A140V	O
Mecp2	B-GP
mutant	O
mice	B-OG
(	O
Mecp2A140V	O
).	O

This	O
MeCP2	B-GP
mutation	O
has	O
also	O
been	O
described	O
in	O
cases	O
of	O
X	O
-	O
linked	O
mental	B-DS
retardation	I-DS
and	O
manic	B-DS
-	I-DS
depressive	I-DS
behaviors	O
.	O

A140V	O
mutant	O
mice	B-OG
produce	O
a	O
mutant	O
MeCP2	B-GP
protein	O
that	O
lacks	O
the	O
ability	O
to	O
bind	O
to	O
Alpha	B-GP
thalassemia	I-GP
/	I-GP
mental	I-GP
retardation	I-GP
syndrome	I-GP
X	I-GP
-	I-GP
linked	I-GP
(	O
ATRX	B-GP
)	O
protein	O
.	O

These	O
mice	B-OG
have	O
an	O
apparently	O
normal	O
life	O
span	O
,	O
and	O
lack	O
specific	O
phenotypes	O
that	O
are	O
displayed	O
in	O
other	O
mouse	B-OG
models	O
including	O
seizures	O
,	O
tremors	O
,	O
and	O
breathing	O
irregularities	O
.	O

However	O
they	O
show	O
increased	O
cellular	O
packing	O
and	O
reduced	O
dendrite	O
branching	O
similar	O
to	O
what	O
is	O
observed	O
in	O
autopsy	O
brains	O
from	O
RTT	B-DS
individuals	O
[	O
162	O
].	O

MeCP2	B-GP
partners	O
with	O
ATRX	B-GP
and	O
is	O
involved	O
in	O
the	O
silencing	O
of	O
imprinted	O
genes	O
in	O
brain	O
[	O
163	O
].	O

Recently	O
,	O
a	O
Mecp2e1	O
-	O
deficient	O
mouse	B-OG
model	O
was	O
developed	O
with	O
a	O
point	O
mutation	O
in	O
exon	O
1	O
changing	O
translational	O
start	O
site	O
of	O
the	O
first	O
exon	O
from	O
“	O
ATG	O
”	O
into	O
“	O
TTG	O
”.	O

These	O
mice	B-OG
show	O
many	O
phenotypes	O
observed	O
in	O
Mecp2	B-GP
null	O
mice	B-OG
including	O
hindlimb	O
clasping	O
,	O
forelimb	O
stereotypy	O
,	O
and	O
excessive	O
grooming	O
followed	O
by	O
death	O
within	O
7	O
to	O
31	O
weeks	O
[	O
164	O
].	O

In	O
order	O
to	O
demonstrate	O
the	O
functions	O
of	O
neuronal	O
activity	O
-	O
dependent	O
phosphorylation	O
at	O
S80	O
,	O
S421	O
and	O
S424	O
,	O
two	O
knock	O
-	O
in	O
mice	B-OG
models	O
were	O
generated	O
;	O
Mecp2S80A	O
and	O
Mecp2S421A	O
;	O
S424A	O
abolishing	O
the	O
phosphorylation	O
at	O
S80	O
and	O
S421	O
sites	O
.	O

The	O
Mecp2S80A	O
mice	B-OG
showed	O
reduced	O
locomotion	O
while	O
opposite	O
locomotors	O
behaviors	O
were	O
seen	O
in	O
Mecp2S421A	O
;	O
S424A	O
,	O
providing	O
insights	O
on	O
the	O
functions	O
of	O
S80	O
phosphorylation	O
in	O
resting	O
neurons	O
and	O
S421	O
in	O
active	O
neurons	O
[	O
165	O
].	O

A	O
rat	B-OG
model	O
of	O
Rett	B-DS
Syndrome	I-DS
was	O
also	O
generated	O
with	O
reduced	O
Mecp2	B-GP
expression	O
in	O
the	O
brain	O
.	O

This	O
RTT	B-DS
rodent	O
model	O
revealed	O
reduced	O
expression	O
of	O
Bdnf	B-GP
,	O
with	O
no	O
significant	O
phenotypes	O
that	O
mimic	O
RTT	B-DS
[	O
166	O
].	O

Other	O
RTT	B-DS
animal	B-OG
models	O
include	O
the	O
Drosophila	B-OG
and	O
zebrafish	B-OG
models	O
.	O

The	O
Drosophila	B-OG
RTT	B-DS
model	O
was	O
generated	O
by	O
overexpressing	O
known	O
RTT	B-DS
mutations	O
such	O
as	O
R294X	O
and	O
R106W	O
,	O
which	O
resulted	O
in	O
locomotary	O
dysfunction	O
[	O
167	O
].	O

The	O
recently	O
reported	O
zebrafish	B-OG
model	O
of	O
RTT	B-DS
was	O
generated	O
by	O
introducing	O
a	O
C	O
to	O
T	O
transition	O
-	O
mutation	O
at	O
position	O
187	O
of	O
the	O
Mecp2	B-GP
coding	O
sequence	O
.	O

This	O
resulted	O
in	O
a	O
nonsense	O
mutation	O
and	O
a	O
truncation	O
of	O
the	O
MeCP2	B-GP
protein	O
at	O
the	O
position	O
63	O
(	O
Mecp2Q63	O
*).	O

RTT	B-DS
zebrafish	B-OG
model	O
display	O
altered	O
motor	O
behaviors	O
,	O
although	O
the	O
phenotype	O
is	O
weaker	O
in	O
comparison	O
to	O
other	O
Mecp2	B-GP
-	O
deficient	O
animal	B-OG
models	O
.	O

In	O
contrast	O
to	O
MeCP2	B-GP
-	O
null	O
mouse	B-OG
models	O
,	O
Mecp2	B-GP
-	O
null	O
zebrafish	B-OG
are	O
viable	O
and	O
fertile	O
[	O
168	O
].	O

Other	O
than	O
animal	B-OG
models	O
,	O
in	O
vitro	O
cellular	O
models	O
of	O
Mecp2	B-GP
dysfunction	O
have	O
also	O
been	O
established	O
in	O
order	O
to	O
better	O
understand	O
the	O
how	O
the	O
effects	O
of	O
MeCP2	B-GP
deficiency	O
impairs	O
normal	O
brain	O
function	O
.	O

Loss	O
of	O
Mecp2	B-GP
from	O
cultured	O
neuronal	O
cell	O
populations	O
obtained	O
from	O
embryonic	O
or	O
postnatal	O
Mecp2	B-GP
-	O
deficient	O
mice	B-OG
indicate	O
biochemical	O
and	O
morphological	O
abnormalities	O
similar	O
to	O
Mecp2	B-GP
null	O
animals	B-OG
[	O
49	O
,	O
159	O
,	O
169	O
].	O

Moreover	O
,	O
other	O
studies	O
have	O
revealed	O
putative	O
roles	O
of	O
MeCP2	B-GP
in	O
astrocytes	O
and	O
microglia	O
despite	O
the	O
low	O
levels	O
of	O
MeCP2	B-GP
in	O
these	O
cell	O
types	O
.	O
Mecp2	B-GP
-	O
deficient	O
astrocytes	O
and	O
microglia	O
have	O
been	O
demonstrated	O
to	O
produce	O
aberrant	O
levels	O
of	O
soluble	O
factors	O
,	O
such	O
as	O
glutamate	O
,	O
which	O
inhibit	O
dendrite	O
branching	O
from	O
co	O
-	O
cultured	O
neurons	O
in	O
vitro	O
[	O
47	O
,	O
48	O
,	O
170	O
].	O

In	O
addition	O
,	O
loss	O
of	O
Mecp2	B-GP
from	O
astrocytes	O
has	O
been	O
demonstrated	O
to	O
affect	O
astrocytic	O
gap	O
junction	O
function	O
,	O
thereby	O
resulting	O
in	O
their	O
failure	O
to	O
adequately	O
support	O
dendritic	O
development	O
[	O
48	O
].	O
Table	O
2	O
presents	O
an	O
overview	O
of	O
animal	B-OG
models	O
that	O
are	O
developed	O
to	O
study	O
the	O
molecular	O
function	O
of	O
MeCP2	B-GP
.	O

5	O
.	O

Closing	O
Remarks	O

Epigenetic	O
regulation	O
of	O
gene	O
expression	O
is	O
fundamental	O
for	O
proper	O
organism	O
development	O
and	O
function	O
.	O

MeCP2	B-GP
is	O
a	O
multifunctional	O
epigenetic	O
regulator	O
and	O
the	O
malleability	O
in	O
its	O
function	O
underscores	O
its	O
role	O
in	O
many	O
human	B-OG
diseases	O
.	O

Since	O
its	O
discovery	O
,	O
significant	O
progress	O
has	O
been	O
made	O
to	O
understand	O
its	O
dynamic	O
molecular	O
properties	O
,	O
and	O
increasing	O
evidence	O
reveals	O
its	O
central	O
position	O
in	O
many	O
neurological	O
,	O
neurodevelopmental	O
,	O
neuropsychiatric	O
and	O
non	O
-	O
neurological	B-DS
disorders	I-DS
.	O

Despite	O
tremendous	O
progress	O
in	O
understanding	O
the	O
molecular	O
mechanisms	O
by	O
which	O
dysregulation	O
of	O
MeCP2	B-GP
expression	O
and	O
function	O
results	O
in	O
these	O
disorders	O
,	O
we	O
are	O
still	O
far	O
from	O
translating	O
this	O
knowledge	O
towards	O
effective	O
therapeutic	O
approaches	O
.	O

The	O
availability	O
of	O
excellent	O
animal	B-OG
models	O
promises	O
,	O
not	O
only	O
hope	O
,	O
but	O
also	O
a	O
better	O
strategy	O
to	O
overcome	O
the	O
challenge	O
of	O
translational	O
research	O
.	O

It	O
is	O
very	O
likely	O
that	O
the	O
number	O
of	O
diseases	O
associated	O
with	O
MeCP2	B-GP
dysfunction	O
will	O
grow	O
rapidly	O
in	O
near	O
future	O
,	O
thus	O
,	O
a	O
better	O
understanding	O
of	O
how	O
MeCP2	B-GP
functions	O
in	O
complex	O
regulatory	O
networks	O
will	O
pave	O
the	O
way	O
for	O
the	O
discovery	O
of	O
better	O
disease	O
biomarkers	O
as	O
well	O
as	O
novel	O
targets	O
for	O
treatments	O
.	O

Conflicts	O
of	O
Interest	O

The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Human	O
diseases	O
associated	O
with	O
Methyl	O
CpG	O
binding	O
protein	O
2	O
(	O
MeCP2	O
)	O
and	O
gender	O
mostly	O
affected	O
.	O

Disease	O

Gender	O
mostly	O
affected	O

References	O

Rett	O
Syndrome	O

Females	O
(	O
also	O
males	O
with	O
kleinfelter	O
syndrome	O
47	O
XXY	O
,	O
or	O
somatic	O
mosaicism	O
)	O

[	O
15	O
,	O
62	O
,	O
63	O
,	O
148	O
]	O

MECP2	O
duplication	O
disorder	O

Males	O

[	O
81	O
–	O
83	O
]	O

Angelman	O
Syndrome	O

Females	O

[	O
91	O
,	O
93	O
]	O

X	O
-	O
linked	O
mental	O
retardation	O

Males	O

[	O
86	O
,	O
94	O
,	O
95	O
]	O

Severe	O
neonatal	O
encephalopathy	O

Males	O

[	O
95	O
,	O
97	O
,	O
98	O
]	O

Autism	O

Both	O

[	O
100	O
–	O
102	O
]	O

Fetal	O
alcohol	O
spectrum	O
disorders	O

Both	O
(	O
Studies	O
from	O
animal	O
models	O
only	O
)	O

[	O
109	O
,	O
110	O
,	O
113	O
]	O

Huntington	O
’	O
s	O
disease	O

Both	O

[	O
117	O
]	O

Early	O
-	O
onset	O
schizophrenia	O

Both	O

[	O
106	O
]	O

Cancers	O

Both	O

[	O
119	O
–	O
128	O
,	O
149	O
]	O

Systemic	O
lupus	O
erythematosus	O

Females	O

[	O
56	O
,	O
133	O
,	O
134	O
]	O

Rheumatoid	O
arthritis	O

Females	O

[	O
140	O
,	O
141	O
]	O

Hirschsprung	O
’	O
s	O
disease	O

Males	O

[	O
147	O
]	O

Animal	O
models	O
of	O
MeCP2	O
dysfunction	O
.	O

Animal	O
models	O

Description	O

Phenotype	O

References	O


Mouse	O

Mecp2	O
null	O
mouse	O
models	O
:	O

Exon	O
3	O
and	O
4	O
deletion	O
.	O

MeCP2	O
expression	O
and	O
function	O
are	O
abolished	O

Unusual	O
gait	O
,	O
hindlimb	O
clasping	O
,	O
seizures	O
,	O
irregular	O
breathing	O

[	O
150	O
,	O
151	O
]	O

Mecp2tm1	O
.	O
1bird	O

Mecp2tm1	O
.	O
Tam	O

Mecp2lox	O
Stop	O
/	O
y	O
or	O
Mecp2tm2	O
.	O
bird	O

Gene	O
silencing	O
by	O
Cre	O
recombinase	O
insertion	O
into	O
intron	O
2	O
.	O
No	O
protein	O
is	O
detected	O
(	O
behaves	O
as	O
a	O
null	O
allele	O
)	O

Phenotypes	O
similar	O
to	O
the	O
null	O
mice	O
with	O
abnormal	O
behavior	O
,	O
RTT	O
-	O
like	O
phenotypes	O
and	O
breathing	O
irregularities	O
.	O

[	O
153	O
]	O


Mecp2	O
mutant	O
mice	O
:	O

Mecp2tm1	O
.	O
1jae	O

Exon	O
3	O
deletion	O
.	O

MeCP2	O
expression	O
and	O
function	O
are	O
abolished	O
.	O

Neurological	O
phenotype	O
similar	O
to	O
Mecp2	O
null	O
mice	O
,	O
however	O
lifespan	O
is	O
longer	O
.	O

[	O
155	O
]	O

Mecp2308	O

Introduction	O
of	O
a	O
premature	O
STOP	O
codon	O
in	O
exon	O
4	O
.	O
Truncated	O
MeCP2	O
protein	O
with	O
residual	O
unknown	O
function	O

Milder	O
neurological	O
phenotype	O
compared	O
to	O
Mecp2	O
null	O
mice	O

[	O
156	O
]	O


Mecp2	O
conditional	O
-	O
mutant	O
mice	O
:	O

Nestin	O
-	O
cre	O
knockout	O

Brain	O
-	O
specific	O
deletion	O

Similar	O
to	O
Mecp2	O
null	O
mice	O
except	O
for	O
breathing	O
phenotype	O

[	O
150	O
,	O
155	O
]	O

Sim	O
1	O
-	O
cre	O
knockout	O

Selective	O
deletion	O
in	O
neurons	O
of	O
hypothalamus	O
and	O
amygdala	O

Abnormal	O
stress	O
response	O
,	O
stranger	O
aggression	O

[	O
157	O
]	O

TH	O
-	O
cre	O
knockout	O

Selective	O
deletion	O
in	O
dopaminergic	O
and	O
noradrenergic	O
neurons	O
.	O

Hypoactivity	O
,	O
reduced	O
expression	O
of	O
tyrosine	O
hydroxylase	O

[	O
158	O
,	O
159	O
]	O

CamKII	O
-	O
cre	O
knockout	O

Forebrain	O
-	O
specific	O
deletion	O

Impaired	O
motor	O
co	O
-	O
ordination	O
,	O
anxiety	O

[	O
171	O
]	O

Pet1	O
-	O
cre	O
knockout	O

Selective	O
deletion	O
in	O
serotonergic	O
neurons	O

Increased	O
aggression	O
,	O
hyperactivity	O

[	O
159	O
]	O

Viaat	O
-	O
cre	O
knockout	O

Selective	O
deletion	O
in	O
GABAergic	O
neurons	O

Reduced	O
lifespan	O
,	O
self	O
-	O
mutilation	O

[	O
169	O
]	O


Mice	O
overexpressing	O
MECP2	O

MeCP2Tg1	O

MECP2	O
overexpression	O
in	O
all	O
cells	O

Seizures	O
,	O
premature	O
death	O
,	O
abnormal	O
social	O
behaviors	O
,	O
hypoactivity	O

[	O
160	O
]	O

Tau	O
-	O
MECP2	O
-	O
rescue	O

MECP2	O
overexpression	O
in	O
neurons	O

Hypoactivity	O
,	O
impaired	O
cognition	O

[	O
81	O
]	O


Rett	O
Syndrome	O
mouse	O
models	O
:	O

Mecp2R168X	O

Premature	O
STOP	O
codon	O
at	O
amino	O
acid	O
168	O

Hindlimb	O
clasping	O
,	O
breathing	O
irregularities	O

[	O
161	O
]	O

Mecp2A140V	O

Missense	O
mutation	O
that	O
produces	O
mutant	O
MeCP2	O
protein	O

Normal	O
life	O
span	O
,	O
reduced	O
dendrite	O
branching	O

[	O
162	O
]	O

Mecp2T308A	O

Knock	O
-	O
in	O
mutation	O
that	O
causes	O
loss	O
of	O
interaction	O
with	O
NCoR	O
complex	O

Motor	O
abnormalities	O
,	O
hindlimb	O
clasping	O

[	O
172	O
]	O

Mecp2R306C	O

Knock	O
-	O
in	O
mutation	O
that	O
causes	O
loss	O
of	O
interaction	O
with	O
NCoR	O
/	O
SMRT	O

Impaired	O
motor	O
function	O
,	O
hindlimb	O
clasping	O

[	O
173	O
]	O

Mecp2T158A	O

Knock	O
-	O
in	O
mutation	O
that	O
disrupts	O
protein	O
stability	O

Developmental	O
regression	O
,	O
hypoactivity	O

[	O
174	O
]	O

Mecp2	O
-	O
e1	O

Point	O
mutation	O
of	O
ATG	O
in	O
exon	O
1	O
to	O
TTG	O

Forelimb	O
stereotypy	O
,	O
hindlimb	O
clasping	O
,	O
excessive	O
grooming	O
,	O
and	O
hypoactivity	O

[	O
164	O
]	O

Mecp2S80A	O

Knock	O
-	O
in	O
mouse	O
model	O
with	O
abolished	O
phosphorylation	O
at	O
S80	O
.	O

Reduced	O
locomotion	O
similar	O
to	O
that	O
of	O
Mecp2	O
null	O
mice	O
and	O
RTT	O
patients	O

[	O
165	O
]	O

Mecp2S421A	O
;	O
S424A	O

Double	O
mutant	O
mouse	O
model	O
which	O
lacks	O
phosphorylation	O
at	O
both	O
S421A	O
and	O
S424A	O

Phenotypes	O
opposite	O
to	O
Mecp2S80A	O
mice	O
(	O
increased	O
locomotion	O
)	O

[	O
165	O
]	O


Mecp2	O
Mouse	O
models	O
of	O
phenotypic	O
rescue	O

Mecp2lox	O
Stop	O
/	O
y	O
;	O
cre	O
ER	O

Activation	O
of	O
Mecp2	O
gene	O
in	O
Mecp2l	O
°	O
x	O
St	O
°	O
p	O
/	O
y	O
mouse	O
model	O
by	O
cre	O
-	O
ER	O
and	O
Tamoxifen	O
injections	O
.	O

Rescued	O
majority	O
of	O
RTT	O
phenotypes	O
including	O
increased	O
lifespan	O
,	O
delayed	O
disease	O
progression	O

[	O
153	O
]	O

Mecp2	O
+/	O
;	O
CAGGS	O
LSL	O
Mecp2	O

Conditional	O
activation	O
(	O
rescue	O
)	O
of	O
Mecp2	O
gene	O
in	O
brain	O
using	O
synthetic	O
CAGGS	O
promoter	O

Partial	O
rescue	O
of	O
RTT	O
phenotypes	O
,	O
including	O
delayed	O
disease	O
progression	O
,	O
reduced	O
lethality	O
and	O
improved	O
behaviors	O

[	O
154	O
]	O


Rat	O

Mecp2	O
-	O
sh	O
-	O
1	O

Viral	O
mediated	O
RNAi	O
-	O
induced	O
downregulation	O
of	O
Mecp2	O

Transient	O
neurobehavioral	O
abnormalities	O
,	O
reduced	O
Bdnf	O
expression	O
in	O
hippocampus	O

[	O
166	O
]	O


Zebrafish	O

Mecp2Q63	O
*.	O

Nonsense	O
mutation	O
and	O
a	O
truncation	O
of	O
MeCP2	O
at	O
position	O
63	O

Altered	O
motor	O
behaviors	O
,	O
however	O
viable	O
and	O
fertile	O

[	O
168	O
]	O


Drosophila	O

GMR	O
-	O
Gal4	O
:	O
UAS	O
-	O
MeCP2	O
R106W	O
/+.	O
GMR	O
-	O
Gal4	O
:	O
UAS	O
-	O
MeCP2	O
R294X	O
/+.	O

Overexpression	O
of	O
mutant	O
MeCP2	O
protein	O

Locomotar	O
dysfunction	O
,	O
external	O
eye	O
disruption	O

[	O
167	O
]	O

